Join the club for FREE to access the whole archive and other member benefits.

Kapil Bharti

Head of the Ocular and Stem Cell Translational Research Section at NEI.

Senior Investigator

Ocular and Stem Cell Translational Research Section

NEI

Building 10, Room 10B10,10 Center Drive,Bethesda,MD-20892

301-451-9372

kapilbharti@nei.nih.gov


Dr. Bharti holds a bachelor's degree in biophysics from the Panjab University in Chandigarh, India, where he graduated with highest honors. This was followed by a master degree in biotechnology at the Maharaja Sayaji Rao University in Baroda, India and a diploma in molecular cell biology at the Johann Wolfgang Goethe University at Frankfurt in Germany. Supported by an international Ph.D. student fellowship, he obtained his Ph.D. from the same institution, graduating summa cum laude. His Ph.D. work involved basic biology in the areas of heat stress, cellular chaperones, and epigenetics. From Germany, Dr. Bharti came to the National Institute of Neurological Disorders and Stroke to work with Dr. Heinz Arnheiter as a postdoctoral fellow. While there, he published numerous papers in the areas of transcription factor regulation, pigment cell biology, and the developmental biology of the eye. It is perhaps this combination of diverse backgrounds that led him to develop an interest in the emerging field of stem cell biology, particularly of the retinal pigment epithelium, as he moved into the role of staff scientist. Dr. Bharti has authored numerous publications and has won several awards, including, most recently, being a finalist in the prestigious trans-NIH Earl Stadtman Symposium.

Visit website: https://irp.nih.gov/pi/kapil-bharti

 kapilbharti

See also: Institute National Eye Institute (NEI) - Performs and supports vision research and education programs

Details last updated 16-Apr-2020

Kapil Bharti News

3D bioprinted retina tissue uncovers advanced age-related macular degeneration

Medgadget - 06-Jan-2023

Researchers are making strides in developing advanced in vitro tissue models to study eye diseases

Read more...

Cellino Biotech raises $80m to upscale its automated stem cell production

TechCrunch - 25-Jan-2022

Fast, cheap and plentiful iPSCs will be needed for clinical trials and new treatments

Read more...

Start-ups to scale manufacturing of stem-cell therapies for practical use

Nature - 29-Sep-2021

Challenges of mass producing stem cells and how 3 companies are attempting to overcome them

Read more...

A new faster technique restores vision in mice with retinal degeneration

National Institutes of Health (NIH) - 15-Apr-2020

Researchers plan clinical trials of this in humans to treat retinal diseases

Read more...

NIH launches clinical trial to test new therapy for macular degeneration

National Institutes of Health (NIH) - 16-Dec-2019

Patient-derived induced pluripotent stem cells to replace dead retinal cells

Read more...